Breast Cancer
By Phoebe Starr
A new study presented at the 2018 American Association for Cancer Research meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›
Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them. Read More ›
Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent. Read More ›
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from the disease in 2017. For the majority (62%) of women with breast cancer, the disease is confined to the breast, and the 5-year survival approaches 100%. However, for women with metastatic disease, the likelihood of survival at 5 years drops to 27%. Read More ›
Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease. Read More ›
Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.
Read More ›
This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer. Read More ›
Dr Matthew Goetz addresses common questions that arise when patients with HER+ metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor. Read More ›
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy. Read More ›
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer. Read More ›